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Abstract 
Background: It is established that adipose‑derived stem cells (ADSCs) produce and secrete cytokines/growth fac‑
tors that antagonize mucosal injury. However, the exact molecular basis underlying the treatment effects exerted by 
ADSCs is ill understood, and whether ADSCs cooperate with adipose tissue particles to improve mucosal function 
in patients with empty nose syndrome (ENS) has not been explored. We investigated the impact of ADSCs on nasal 
mucosa, the associated mechanisms, and their use in the treatment of patients with ENS.
Results: The nasal endoscope and mucociliary clearance assessments were significantly improved (P < 0.05) in 
patients with (n = 28) and without (n = 2) a rudimentary turbinate that received ADSCs combined with fat granules 
transplantation. Patients experienced a significant improvement in nasal obstruction and nasal mucociliary clear‑
ance after nasal turbinate angioplasty (P < 0.05). H&E staining, Masson’s staining, and AB‑PAS staining confirmed that 
inflammation was significantly reduced, collagenous fibers became aligned, fewer deposits were observed, and the 
mucosal proteins generated from caliciform cells increased following treatment. After a 14‑day incubation period, 
ADSCs developed a polygonal cobblestone shape characteristic of human epithelial cells. Furthermore, immunohisto‑
chemical analysis revealed the presence of epithelial markers such as cytokeratin‑7, and cytokeratin‑19. Western blot 
analysis showed the presence of specific epithelial cell markers including cytokeratin‑7, cytokeratin‑14 and cytokera‑
tin‑19 in these epithelial like cells (ELC); these markers had low expression levels of ADSCs.
Conclusions: The reconstruction of mucosal function by nasal turbinate angioplasty combined with ADSCs and 
autologous adipose tissue particle transplantation significantly improved the symptoms of patients with ENS. This is a 
new procedure that will improve mucosal restoration treatment options in patients with ENS. Furthermore, we under‑
took preliminary explorations of the underlying mechanisms involved, and found that transplantation of ADSCs could 
induce epithelial cells to improve mucosa function in patients with ENS in the micro‑environment of injection areas.
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Background
In recent years, rapid developments in regenerative 
medicine have identified seed cells and applicable cell 
stroma for tissue engineering to restore tissue damage. 
Adipose-derived stem cells (ADSCs) are excellent tissue 
engineering seed cells with several advantages compared 
to other stem cells: they are abundant in source, easy to 
find and culture, not rejected, safe, will undergo trans-
layer multiple differentiation, and proliferate rapidly 
[1–4]. Empty nose syndrome (ENS) is an iatrogenic dis-
order most often recognized by the presence of paradoxi-
cal nasal obstruction despite an objectively wide, patent 
nasal fossa. The term ‘empty nose syndrome’ was initially 
used to describe certain symptoms associated with tissue 
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loss and radiographic findings of a paucity of normal 
anatomic structures within the nasal cavities. After the 
removal of the inferior nasal concha, 20 % of patients will 
develop ENS [5, 6]. The severity of the subjective sensa-
tion caused by ENS does not correlate with the findings 
of objective examinations and can cause conflict between 
patients and doctors. There is no established treatment 
for the nasal symptoms experienced by patients with 
ENS; developing such treatments is an important clinical 
priority.
Results
ADSC transplantation improved nasal mucosal clinical 
symptoms
Flow cytometric analysis demonstrated that ADSCs were 
positive for CD73, CD90, and CD105, and negative for 
CD19, CD34, CD45, and HLA-DR (Fig.  1). The ADSCs 
were also capable of osteogenic and adipogenic differen-
tiation when cultured in the appropriate inducing media. 
Assessment of the degree of osteogenic and adipogenic 
diffentiation via Alizarin Red S and Oil Red O staining, 
respectively, revealed good results (Fig. 2). Following the 
transplantation of ADSCs and fat particles into the areas 
of nasal damage to form turbinates, 30 ENS patients dis-
played no signs of infection or allergy. Of these patients, 
symptoms improved in 28, including increased moisten-
ing of the nasal mucosa, decreased tension of the mucosa 
and of nasal cavity pain when breathing, and improved 
quality of sleep. Two patients experienced improvement 
of nasal cavity dryness. However, excessive breathing 
remained an issue. 
ADSCs transplantation improved the function of the nasal 
mucosa in patients with ENS
Nasal endoscopy was conducted 3 months after treatment, 
and the nasal cavities of patients were visibly more erythe-
matous, secreted more mucus and had fewer scabs (Fig. 3).
Mucociliary clearance (MCC) assessments
Saccharine clearance times were 1526.23  ±  1000.43  s 
preoperatively, 1457.13  ±  1078.23  s at 3  months fol-
low-up, 1232.03 ±  499.45  s at 6  months follow-up, and 
1501.00 ± 1159.85 s at 9 months follow-up. Mucociliary 
clearance assessments showed improvement of saccha-
rine clearance times in the study group at 3 and 6 months 
postoperatively (Fig. 4).
Acoustic rhinometry assessments: ADSCs improved 
nasal resistance and mucociliary clearance assessments, 
and reduced the nasal volumes and the cross‑sectional 
areas of the nasal cavities of patients with ENS
Acoustic rhinometry assessments showed improve-
ments in nasal resistance (NAR), mucociliary clearance 
assessments (MCCs), nasal volumes (NVs), and in the 
minimum cross-sectional areas (MCAs) of the nasal 
cavities of patients at 3, 6, and 9 months postoperatively. 
The improvements in NAR and in MCAs were not sta-
tistically significant at 3 and 6 months after surgery, but 
where so, when compared to the initial visit, 9  months 
after surgery (*P < 0.05). The values of NV reduced after 
the implantation surgery and the change of NV average 
overall scores were statistically significant between the 
initial visit versus those of 3 and 9  months after treat-
ment (*P  <  0.05). One patient has been observed over 
a period of 18  months. The symptoms of nasal crust-
ing and difficulty with nasal breathing improved further 
(data not shown). The acoustic rhinometry and endo-
scopic imaging findings were not significantly different 
9  months after surgery. However, the saccharine clear-
ance time was greatly improved at 18 months compared 
to that at 12  months after surgery (data not shown) 
(Fig. 4).
ADSC transplantation treatment improved the histological 
appearance of the nasal mucosa of patients with ENS
Lymphocytes and neutrophils infiltrated the nasal 
mucosa prior to ADSCs injection (Fig.  5a). After 
ADSCs injection, the nasal mucosa section had fewer 
infiltrated lymphocytes and neutrophils 30 days follow-
ing treatment (Fig. 5b). Deposits of thickened and dis-
organized collagenous fibers were seen using Mason’s 
staining between the glands in the nasal mucosa prior 
to ADSC injection (Fig. 5c). Thirty days later, the colla-
genous fibers were aligned in the nasal mucosa, and col-
lagenous fiber deposition was decreased in the glands 
(Fig.  5d). As revealed by AB-PAS staining of mucosa 
tissue, mucosal proteins generated from cyathiform 
cells were limited and the submucosal glands showed 
compensatory hyperplasia (Fig.  5e). Thirty days later 
the mucosal proteins generated from cyathiform cells 
were evenly distributed throughout the nasal mucosa 
(Fig. 5f ).
Differentiated human ADSCs expressed epithelial markers
After 14  days of ADSC culture in a differentiating 
medium containing 20–30  ng/ml EGF, 20–30  % of the 
cells acquired a rounded/polygonal shape. They prolifer-
ated, and formed an adherent monolayer, organized in 
cobblestone-pattern clusters (Fig. 6). While pure popula-
tions of ADSCs downregulated the expression of cytoker-
atin 19 (CK19), immunohistochemical analysis revealed 
that the differentiated cells from the dark blue cobble-
stone-pattern clusters were positive for CK19 (Fig.  6). 
Microscopic analysis using Lucia software (Nikon Corpo-
ration Co., Kanagawa, Japan), showed that these consti-
tuted approximately 60 % of the total cells.
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Sustained upregulation of CK7, CK14 and CK19 in ADSCs 
leads to an increase in and the activation of epithelial‑like 
cells revealed by western blotting
To demonstrate the progressive epithelial determination 
of ADSCs, multiple markers specific for epithelial cells 
were selected and evaluated using western blot analy-
sis. As shown in Fig.  7, cytokeratin-7 (CK7), cytokera-
tin-14 (CK14), and cytokeratin-19 (CK19) were mainly 
expressed in epithelial-like cells (ELC), but rarely in 
ADSCs.
Discussion
ENS often occurs several months or years following 
nasal cavity surgery, and the diagnosis mainly relies 
on objective symptoms, signs, and the clinical history. 
Researchers have hypothesized that decreased nasal 
Fig. 1 Flow cytometric analysis. ADSCs are positive for CD73, CD90, and CD105, and negative for CD19, CD34, CD45, and HLA‑DR
Page 4 of 9Xu et al. Cell Biosci  (2015) 5:54 
mucosa and changes in nasal resistance participate in 
the occurrence of ENS [7]. The nasal mucosa has glands 
and receptors to heat, humidify, and clean the inspired 
air, as well as immune functions. The specific anatomi-
cal structure of the nose adjusts the nasal cavity airflow 
and laminar conditions. Patients with ENS complain 
of reduced quality of life as a result of reduced nasal 
functions.
The protection of the nasal mucosa and prevention of 
ENS following nasal cavity surgeries are a major concern 
among otolaryngologists. Surgeons use hydroxyapatite, 
autogenous cartilage [8], Medpor, Gore-Tex, or acellu-
lar dermal tissue to support the nasal mucosa of patients 
with ENS and improve nasal resistance and ventilation. 
These treatments are effective, but their effect on the 
recovery of ENS mucosa function is unclear.
This study identified that the injection of ADSCs com-
bined with fat particles during intranasal minimal inva-
sive-turbinate shaping surgery to treat ENS is an effective 
treatment option. ADSCs possess many advantages, 
including a wide range of sources, easy access, minor tis-
sue damage after injections, rapid proliferation, a stable 
phenotype and heredity, low immunogenicity, and the 
potential to differentiate into mesoblastic adipose cells, 
osteoblasts, chondrocyte, vADSCsular endothelial cells, 
and epidermal cells, among others. The expansion of 
ADSCs in vitro will increase the rate of survival of trans-
planted cells, and improve the revADSCsularization of 
transplanted cells, decrease the rate of absorption, lique-
faction, and fat cell infection for a successful single trans-
plant shaping effect [8–10]. Patients given this treatment 
experience an improvement of symptoms associated with 
dryness of the nasal cavity and contradictory nasal resist-
ance [11]. Although contradictory nasal resistance indi-
cates that patients feel a subjective nasal obstruction, it 
is not consistent with nasal examinations that find sub-
stantially widened nasal cavity volumes [12]. Following 
surgery, the heating and humidifying functions of nasal 
cavity patients were greatly improved, and the pain in the 
face and nasal cavity disappear when breathing, which 
resulted in improved quality of sleep. Therefore, ADSCs 
and fat particles used in intranasal minimal invasive-
turbinate shaping surgery, rebuild the ENS nasal mucosa 
of patients, enhance the area of turbinate mucosa, and 
improve nasal cavity physiological functioning.
All body surfaces and cavities, including the skin, gas-
trointestinal tract, urogenital system and breast ducts are 
lined by epithelial tissue. This provides a protective bar-
rier. Cell loss from it must be precisely balanced by cell 
Fig. 2 Characterization of ADSCs. Adipogenic differentiation of ADSCs was assessed by Oil Red O staining. The arrow indicates a lipid droplet. The 
osteogenic ability of the ADSCs was assessed using Alizarin red staining. The arrow shows a calcium nodule. Magnification: ×400 (a) and ×400 (b)
Fig. 3 Nasal endoscopy. Prior to the injection of fat tissue combined 
with ADSCs (a, c). Recovery of the nasal turbinate morphology (Aster-
isk was shown). The nasal mucosa rhinothrix has grown (b, indicated 
by the arrow). The nasal cavity became more erythematous, and 
secreted more mucus (d, indicated by the arrow)
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production, in order to maintain epithelial homeosta-
sis. The source of the cells involved in tissue repair after 
injury is largely unknown and is controversial. One pos-
sible source is stem-like progenitor cells. These are prob-
ably the most important, but are rare components of the 
proliferative compartment of epithelial tissues. They have 
been identified in a variety of tissues including neural 
[13], vADSCsular [14], hepatic [15], pancreatic [16] and 
epidermal [17]. Several studies have shown that MSCs, 
HSCs and unfractionated bone-marrow derived cells can 
give rise, in vivo, to epithelial cell types in lung and other 
tissues [18–21].
The nasal epithelial coils have two important func-
tions; they act as a protective barrier and are involved 
in the transport of ions and water. Epithelial ion and 
water transportation is the basis of mucociliary transport 
[22–26].
Nasal mucosa epithelial cells are mainly composed of 
four types of cells: ciliated columnar cells, Non-ciliated 
columnar epithelium (75 %), basal cells (5 %) and mucous 
cells [27, 28]. Basal cells are located in the deepest parts 
of the epithelial layer, and are anchored to the basilar 
membrane by hemidesmosomes [29], were not exposed 
to the cavosurface of cells layer. CK 14 is expressed on 
their surface. Basal cells have the ability to differenti-
ate into the mucus cilium, and they have important 
roles in epithelial injury repair [28, 30]. CK7 and CK19 
are amongst the most basic cell keratin groups in nasal 
epithelial cells [31]. We concluded that the increase of 
cytokine 7, 14 and 19 secretion from ELC enhanced the 
number of basal cells in the transplantation area avail-
able for differentiating into mucus cilium, and that this 
improved the nasal mucosa function in patients with 
ENS. In addition, undoubtedly, ADSC transplantation 
also increased the survival of transplanted adipocytes. 
Both mechanisms may play a part in shaping the turbi-
nate and increasing the area of the nasal mucosa.
This study used fat particles combined with ADSCs 
during intranasal minimally invasive, turbinate shaping 
surgery in 30 patients with ENS. The results indicate that 
the treatment was effective. However, further research 
will be needed to verify the clinical effect and mechanism 
of action of ADSC injections.
Conclusion
We found evidence that ADSC transplantation treat-
ment improved the nasal mucosa function of patients 
with ENS, and that combined use of both treatments 
synergistically reconstructed the turbinate morphol-
ogy of patients with ENS. Mechanistically, ADSC trans-
plantation improved the function of epithelial cell by 
up-regulating the expression of CK7, 14, 19 caused by 
the nasal mucosa injury micro-environment. However, 
ENS nasal mucosa reconstruction is complex, involving 
a multitude of signaling pathways and a variety of mol-
ecules. Consequently, other molecular mechanisms may 
also contribute to the beneficial effects seen with ADSC 




Patients with ENS treated in the Skin Regeneration 
Department and Otolaryngological Department of the 
General Hospital of the Armed Police Forces between 
August 2014 and January 2015 were studied. The SCL-90 
physiological Methods Symptom Check List (250 below), 
Self-Rating Anxiety Scale (SAS, medium below), and 
Fig. 4 Values of nasal resistance, Nasal volume, Minimum cross‑
sectional area, and mucociliary clearance before and after surgery. 
a After ADSC injection, the MCA of the nasal cavity is decreased. b 
After ADSCs injection, the MCC of the nasal cilium is decreased. c 
After ADSC injection, the NAR of the nasal cavity is increased. d After 
ADSC injection, the NV of the nasal cavity is increased. All values are 
presented as mean ± SD, n = 28, *P < 0.05
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Self-Rating Depression Scale (SDS, medium below) were 
used to identify participants. We chose 30 patients, 20 
men and 10 women, aged between 22 and 30 years (aver-
age 26), with secondary ENS caused by a bilateral nasal 
cavity operation. All patients were in good health without 
any systemic diseases. The symptoms of the subjects were 
described as aridity of the nasal mucosa, excessive ven-
tilator function, dry and cold inspiration, and poor sleep 
Fig. 5 H&E staining, Masson’s staining and AB‑PAS staining. Prior to the injection of ADSCs (a, c) compared to the findings 30 days after the injec‑
tion of ADSCs (b, d), the nasal mucosa was infiltrated with lymphocytes and neutrophils (b). Furthermore, the collagenous fibers became aligned 
and collagenous fiber deposition (arrow) decreased after treatment (d). After AB‑PAS staining for mucosa tissue, each group of mucosa shows as 
followed figures e and f. Mucosal proteins generated from cyathiform cell were discontinued, and the gland under mucosa experience compensa‑
tory hyperplasia (e); 30 days after ADSC injections (f), mucosal proteins generated from the cyathiform cell were evenly distributed throughout the 
nasal mucosa
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quality. Each patient was inspected by nasal endoscopy 
using the Sino-Nasal Outcome Test 20 (SNOT-20) [32], 
nasal sound resistance, and nasal mucociliary clearance 
investigations prior to surgery. All patients gave written 
informed consent. The study was approved by the Board 
of Ethics of the General Hospital of the Chinese Armed 
Police Forces.
Isolation and preparation of ADSCs
Each individual was tested for communicable diseases by 
regular antigen-specific antibody examinations (includ-
ing for hepatitis, syphilis, and AIDS), to ensure that they 
were in good health. Approximately 15–20 ml of fat par-
ticles was extracted from the lower abdomen and thigh 
by liposuction. The samples were treated with 0.1 % col-
lagenase, trypsin digestion, and centrifuged to remove 
fat. The cells were re-suspended and filtered through 
a 200-mesh sieve, and the samples were centrifuged 
again in order to split red blood cells. The cells were 
then washed twice in PBS, and the extracted cells were 
re-suspended in high glucose DMEM containing 15  % 
fetal bovine serum at an appropriate density in a ster-
ile culture dish. After 4–5 days, media was added to the 
cells and they were passaged every subsequent 3 days by 
0.05  % trypsin digestion when the cells reached a den-
sity of 85 %. At the third generation (P3), all cells were 
examined and free of mycoplasma, human originated 
particular virus, and endotoxin in accordance with the 
People’s Republic of China pharmacopoeia 2010 (edition 
3, Appendix A). Tests to confirm cell form and activity, 
karyotype, and ADSC immunophenotype were also all 
normal.
Immunophenotyping by flow cytometry
ADSC surface marker analysis using flow cytometry was 
performed on a FACS Calibur unit (Becton–Dickin-
son Biosciences, San Jose, CA, USA). Cells were stained 
with phycoerythrin-conjugated antibodies for CD19, 
CD34, CD11b, CD105, CD73, CD90, CD45 and HLA-
DR (Becton–Dickinson Biosciences). For osteogenic 
and adipogenic differentiation, ADSCs were incubated 
with MesenCult Osteogenic or Adipogenic Stimula-
tory Medium (STEMCELL Technologies, Vancouver, 
Canada) for 2–3  weeks. Osteogenic and adipogenic dif-
ferentiation was evaluated using Alizarin Red S and Oil 
Red O (Sigma-Aldrich, St. Louis, MO, USA) staining, 
respectively.
Fig. 6 Epithelial‑like morphology. The ADSCs with a fusiform shape after Giemsa’s staining were used as negative controls. Immunocytochemical 
analysis of the differentiated cells from cobblestone‑pattern clusters (arrow) showed that they were positive for CK‑19. Magnification: ×40 (a) and 
×400 (b). Scale bars are 100 µm
Fig. 7 ELC expression of epithelial markers. We evaluated ADSC 
trans‑differentiation into ELC using several epithelial markers, includ‑
ing CK7, CK14 and CK19. Western blot analysis ELC showed high 
expression of CK7, CK14 and CK19 proteins. However, a small number 
of bands were detected in ADSCs
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Adipogenic and Osteogenic differentiation
ADSCs were further tested for their ability to differenti-
ate into adipogenic lineages [33]. To achieve this, ADSCs 
were seeded in 12-well plates at a concentration of 
46104 cells/ml and cultured in adipogenic differentiation 
medium (StemPro, Gibco, and Grand Island, NY). After 
7  days in culture, cells were fixed in 4  % paraformalde-
hyde and the intracellular lipid content were visualized 
using Oil Red O. Briefly, cells were fixed with 10 % forma-
lin for 1 h at room temperature. Then, they were washed 
with DI water and prepared by adding 60 % isopropanol 
for 5 min at room temperature. After 5 min, the isopro-
panol was discarded and the cells were incubated with 
Oil Red O working solution (Fisher Scientific) for 5 min 
at room temperature. The Cells were then washed with 
tap water. Hematoxilin was used as counterstaining. For 
osteogenic differentiation, ADSCs were incubated with 
MesenCult Osteogenic Stimulatory Medium (STEM-
CELL Technologies, Vancouver, Canada)for 2–3 weeks. 
Osteogenic differentiation was evaluated using Alizarin 
Red S and (Sigma-Aldrich St. Louis, MO, USA) staining, 
respectively.
Transplantation of ADSCs and fat particles to form a 
turbinate plasty
We treated 30 patients with ENS; some had residual 
turbinates. ADSC injection into areas of nasal mucosa 
damage were conducted every 10  days for a total of 
four injections. For the two ENS patients without 
residual turbinate tissues, the injection of ADSCs to 
areas of nasal mucosal damage were conducted every 
10 days for three injections; furthermore, 1–5 ml autog-
enous fat particles were extracted, and then mixed with 
1  ×  107–5  ×  107 ADSCs (third to sixth generation), 
under the inferior or middle turbinate. Nasal endoscopy, 
nasal sound resistance, and nasal mucociliary clearance 
examinations were conducted at 3, 6, and 9  months 
after treatment.
Outcome measurements
The data of symptom scores, endoscopy, mucocili-
ary clearance (MCC), and acoustic rhinometry (Dan-
ish Rhinomanometer RhinoScan 2000, Interacostics 
A/S, Assens, Denmark) were gathered before and 3, 
6, and 9  months after surgery. We also evaluated the 
mean value of nasal resistance (NAR), nasal volume 
(NV), and nasal minimum cross-sectional area (MCA) 
through an acoustic rhinometry examination. NAR is 
calculated according to Ohm’s law: 1/R  =  1/Rr  +  1/
Rl (R  =  total nasal resistance, Rr  =  right nasal cavity 
resistance, Rl = left nasal cavity resistance). NV is calcu-
lated according to the following formula: NV = Vr + Vl 
(NV = total nasal volume, Vr = volume of the right nasal 
cavity, Vl = volume of the left nasal cavity). MCA is the 
average cross-sectional area of the bilateral nasal cavi-
ties. The assessment of MCC was determined with the 
saccharine method [34].
Tissue histological analysis
Nasal mucosa (0.1 ×  0.1 cm2) were resected before and 
30 days after the injections began and fixed in 10 % for-
malin neutral buffered solution, embedded in polyester 
wax and sectioned into 6-mm slices on polylysine-coated 
glass slides. The sections were subjected to hematoxylin 
& eosin (H&E), Masson’s trichrome, immunohistochem-
istry, and Alcian blue-periodic acid-Schiff (AB-PAS) 
staining.
Masson’s trichome staining was performed with a kit 
from Sigma (St. Louis, MO, USA) according to the man-
ufacturer’s protocol. The collagen fibers were stained 
blue and myocardium was stained red. Immunohisto-
chemistry for collagen I was performed using the SABC 
kit (Maxim, Fuzhou, China) according to the manufac-
turer’s instructions. The tissue sections were incubated 
with primary antibodies against collagen I (1:50 dilution) 
overnight at 4  °C, and then incubated with biotinylated 
secondary antibody for 30 min at room temperature fol-
lowed by 30 min of incubation with streptavidin peroxi-
dase (Dako LSAB + HRP kit). After rinsing the samples, 
the sections were visualized using DAB and the slides 
were counterstained with hematoxylin. All fields was 
taken under a light microscope at 200× magnification.
For AB-PAS staining, tissue sections were immersed in 
a solution of alcian blue and 3 % acetic acid for 30 min. 
Samples were then immersed in Schiff’s reagent for 
15  min to promote oxidation before undergoing a final 
counterstain in hematoxylin.
Differentiation of ADSCs to epithelial‑like cells
Human ADSCs obtained as described above were plated 
in uncoated flasks and entered into the differentiation 
process at the second passage (usually 35–42 days from 
the initial isolation). The culture medium was DMEM 
low-glucose (1 g/l) with 10 % FBS, initially supplemented 
with 8 μg/l epidermal growth factor (EGF, Peprotech Inc., 
Rocky Hill, USA), and 30  % conditioned medium [35]. 
After 7–14  days from the initial plating, when the cells 
acquired a rounded or polygonal shape, the expression of 
the epithelial marker, cytokeratin 19, was assessed.
Western blot analysis
Briefly, human ADSC samples and epithelial-like cells 
were selected using the same method, lysed in RIPA 
buffer and protein lysates and were separated on 8 % SDS 
polyacryamide gel by electrophoresis. The proteins were 
transferred to PVDF membranes, which were incubated 
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with CK7 antibody (Abcam, USA), CK19 antibody 
(Abcam, USA), CK14 antibody (Abcam, USA), and actin 
(BOSTER, Wuhan, China). The membranes were washed 
and incubated with horseradish peroxidase-conjugated 
anti-goat IgG antibody (BOSTER, Wuhan, China). The 
blots were visualized with chemiluminescence.
Statistical analysis
SPSS 19.0 software (SPSS Inc., Chicago, IL, USA) was 
used to conduct statistical analysis and results are shown 
as the mean ± SD. One-way analysis of variance was used 
to compare groups, and we further compared groups of 
two by a one-way analysis of variance analysis. Statistical 
significance was set at P < 0.05.
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